Steven Nissen for FDA deputy commissioner? The Twitterati say no.

On Thursday, MedCity News’ Brandon Glenn floated the idea of Cleveland Clinic’s Steven Nissen replacing US Food & Drug Administration Deputy Commissioner Joshua Sharfstein, who left to head Maryland’s health department.

“A Nissen nomination would symbolically show that Obama won’t back down from a fight with Republicans ’ and perhaps temporarily quiet a liberal base that sees him as at best too willing to cave to the GOP and at worst weak, ineffectual and just another opportunistic politician without any strong core beliefs,” Glenn wrote.

Immediate reaction to the idea through social media was subdued. Some loved the idea and envisioned a feistier FDA with Nissen on board. But others called the idea a “lead balloon.” Another exclaimed: “I hope not!”

Below is a sampling of reaction that pulsed through Twitter in the past 24 hours.

  • @cardiobrief Nissen mentioned as Sharfstein’s replacement, but the odds are very long: http://bit.ly/fyTlXD
  • @adamfeuerstein: If Steven Nissen is named as J. Sharfstein’s replacement at FDA, the biotech/drug stocks will tank and never recover. (via @cardiobrief) $$
  • @maverickny I hope Nissen gets the job, we need more spunk and rigour at the FDA not less
  • @tabloidmed: Sharfstein’s FDA replacement: Why not Cleveland Clinic’s Steven Nissen? \: http://bit.ly/fXgEts Wonder who floated that lead balloon?
  • @SMFleet Nissen should be named hot dog commissioner also.
  • @RPMReportMike great piece on Nissen and FDA. Not gonna happen, but worth thinking about nevertheless.
  • @ddwebster Oh, I hope not! RT @ChristianeTrue: RT @cardiobrief: Nissen mentioned as Sharfstein’s replacement-odds are very long http://bit.ly/fyTlXD

Coincidentally, on the same day we tossed Nissen’s name out as an FDA deputy he was on air showing the kind of thinking that makes him worthy of consideration. He told Bloomberg that drugmakers need to make better drugs and not more of them.

Enhanced by Zemanta
Chris Seper

Chris Seper MedCity News

Chris Seper is the CEO at MedCity Media, which publishes MedCityNews.com. He is also a senior writer at MedCity News. Reach him at chris@medcitynews.com.

more

Comments RSS Post a comment

Certainly it’s possible for the FDA to make missteps and adopt ineffective policies. I think many in the device industry in particular, though, are blinded by personal ideology and short term thinking as to what really benefits their companies and the US in general.

Simply put, the US leads in international medical device sales not only because of our innovativeness and business effectiveness, but also because international end users know that our regulatory system is rigorous. The more muscular the FDA is in public interactions that are reported in international news, the more US devicemakers benefit in a strategic sense.

As a national trade strategy, the FDA should have the toughest rules in the world, and the least tolerance for slackers. US device makers will benefit in direct proportion to the FDA’s international reputation.

Comment by MIREGMGR — January 7, 2011 @ 4:15 pm

Post a Comment

Submit Comment

Be a Thought Leader: Join MedCitizens

Anyone can blog on MedCity News when they become a "MedCitizen." MedCitizens publish their own thoughts about current medical news and the latest issues in healthcare to the entire MedCity News audience.

Click to login or learn more

MedCity Jobs Board


MedCity Whitepapers

Real Time Web Analytics